Compare AstraZeneca plc (AZN) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Marriott International Inc — how do they compare? AstraZeneca plc trades at $166.28 (market cap $253.13B), while Marriott International Inc trades at $362.11 (market cap $95.77B). The key difference: AstraZeneca plc is far larger — about 2.6× Marriott International Inc 's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | MAR | |
|---|---|---|
Market Cap | $253.13B | $95.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $402.54 |
52-Week Low | $137.44 | $255.35 |
Enterprise Value | $279.37B | $112.72B |
Dividend Yield | 1.92% | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Marriott International (MAR) trades at $362.87, down 3.52% today, with a bearish technical signal and mixed earnings history. The company maintains strong revenue growth, reaching $26.19B in 2025, and a net income margin of 9.72%. Recent developments include the launch of Ask Bonvoy AI and expansion to 10,000 properties, though debt levels have risen to 58.83% of assets. Analyst consensus is a $387.33 price target with 44% buy ratings.
The outlook is cautiously optimistic given solid fundamentals and strategic initiatives, but high valuation ratios and increasing leverage pose risks. Near-term performance hinges on Q2 2026 earnings due August 3, 2026, with investor focus on debt management and travel demand sustainability amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
